Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline

Mechanisms of Ageing and Development

Volumn 116, Issue 2-3, 2000, Pages 181-191

  Maruyama, Wakako ^a   Yamamoto, Takako ^b   Kitani, Kenichi ^a   Carrillo, Maria Christina ^c   Youdim, Moussa ^d   Naoi, Makoto ^e  

^a Department of Basic Gerontology   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

^c UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

^d Eve Topf Neurodeg Dis Ctr R   (Israel)

^e Institute of Physical and Chemical Research   (Japan)

Author keywords

Apoptosis; Mitochondrial membrane potential; Neuroprotection; Parkinson's disease; Propargylamine; Rasagiline

Indexed keywords

PROPARGYLAMINE; RASAGILINE; SELEGILINE; UNCLASSIFIED DRUG;

APOPTOSIS; CELL DEATH; CONFERENCE PAPER; DOPAMINERGIC TRANSMISSION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NERVE DEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMAL; APOPTOSIS; HUMAN; INDANS; MOLECULAR STRUCTURE; MOLSIDOMINE; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARGYLINE; PROPYLAMINES; RATS; RATS, INBRED F344; SELEGILINE; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0034738387     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(00)00144-5     Document Type: Conference Paper

References (32)

1. Anglade P., Vyas S., Hirsch E.C., Agid Y. Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol. Histopathol. 12:1997;603-610.
2. Beers R.F. Jr, Sizer J.W. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J. Biol. Chem. 195:1952;133-140.
3. Carrillo M.C., Kanai S., Nokubo M., Ivy G.O., Kitani K. Deprenyl increases activities of both superoxide dismutase and catalase but not of glutathione peroxidase in striatum of young male rats. Life Sci. 48:1991;517-521.
4. Carrillo, M.C., Minami, C., Kitani, K., Maruyama, W., Ohashi, K., Yamamoto, T., Naoi, M., Kanai, S., Youdium, M.B.H., 2000. Enhancing effect of rasagiline on superoxide dismutase (SOD) and catalase (CAT) activities in the dopaminergic system in the rat. Life Sci. (in press).
5. Churchyard A., Mathias C.J., Boonkongchuen P., Lees A.J. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 63:1997;228-234.
6. Engberg G., Elebring T., Nissbrand H. Deprenyl (selegiline), a selective MAO-B inhibitor with active metabolites. J. Pharmacol. Exp. Ther. 259:1991;841-847.
7. Finberg J.P.M., Tenne M., Youdim M.B.H. Tyramine antagonistic properties of AGN-1135 - an irreversible inhibitor of monoamine oxidase type B. Br. J. Pharmacol. 73:1981;65-74.
8. Finberg J.P., Lamensdorf L., Commissiong J.W., Youdim M.B.H. Pharmacology and neuroprotective properties of rasagiline. J. Neural Transm. [Suppl.]. 48:1996;95-101.
9. Finberg J.P.M., Takeshima T., Johnston J.M., Commissiong J.W. Increased survival of dopamine neurons by rasagiline, a monoamine oxidase B inhibitor. NeruReport. 9:1998;703-707.
10. Götz M.E., Breithaupt W., Sautter J., Kupsch A., Schwarz J., Oertel W.H., Youdim M., Riederer P., Gerlach M. Chronic TVP-1012 (rasagiline) dose-activity response of monoamine oxidase A and B in the brain of the common marmoset. J. Neural Transm. [Suppl.]. 52:1997;277-284.
11. Ishitani R., Chuang D.M. Glyceraldehyde-3-phosphate dehydrogenase antisense oligodeoxynucleotides protect against cytosine arabinonucleoside-induced apoptosis in cultured cerebellar neurons. Proc. Natl. Acad. Sci. USA. 93:1996;9937-9941.
12. Ishitani R., Tanaka M., Sunaga K., Katsube N., Chuang D.M. Nuclear localization of overexpressed glyceraldehyde-3-phosphate dehydrogenase in cultured cerebellar neurons undergoing apoptosis. Mol. Pharmacol. 53:1998;701-707.
13. Kragten E., Lalande I., Zimmermann K., Roggo S., Schindler P., Müller D., Oostrum J., Waldmeier P., Fürst P. Glyceraldehyde-3-phosphate dehydrogenase, the putative target of the antiapoptotic compounds CGP 3466 and R-(-)-deprenyl. J. Biol. Chem. 273:1998;5821-5828.
14. Lamensdorf I., Youdim M.B.H., Finberg J.P.M. Effect of long-term treatment with selective monoamine oxidase A and B inhibitors on dopamine release from rat striatum in vivo. J. Neurochem. 67:1996;1532-1539.
15. Li X.M., Juorio A.V., Qi J., Boulton A.A. L-Deprenyl potentiates NGF-induced changes in superoxide dismutase mRNA in PC12 cells. J. Neurosci. Res. 53:1998;235-238.
16. Maruyama W., Naoi M., Kasamatsu T., Hashizume Y., Takahashi T., Kohda K., Dostert P. An endogenous dopaminergic neurotoxin, N-methyl-(R)salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neurochem. 69:1997;322-329.
17. Maruyama W., Takahashi T., Naoi M. Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. J. Neurochem. 70:1998;2510-2515.
18. Maruyama W., Takahashi T., Naoi M. Deprenyl protects human dopaminergic neuroblastoma SH-SY5Y cells from apoptosis induced by peroxynitrite and nitric oxide. Mech. Ageing Dev. 111:1999;175-188.
19. McCord E.F., Fridovich I. Superoxide dismutase. An enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 244:1969;6049-6050.
20. Olanow C.W., Hauser R.A., Gauger L., Malapira T., Koller W., Hubble J., Bushenbark K., Lillienfeld D., Esterlitz J. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann. Neurol. 38:1995;771-777.
21. Oren, S., 1999. Clinical trials with rasagiline mesylate: A new drug for treatment of Parkinson's disease. Parkinsonism Rel. Disord. (in press).
22. Parkinson's Study Group, 1993. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183.
23. Sabbagh A., Youdim M.B.H. Selective inhibition of monoamine oxidase type B by propargyl-containing drugs. Israel J. Med. Sci. 14:1978;1097.
24. Shidoji Y., Nakamura N., Moriwaki H., Muto Y. Rapid loss in the mitochondrial membrane potential during geranylgeranoic acid-induced apoptosis. Biochem. Biophys. Res. Commun. 230:1997;58-63.
25. Speiser Z., Levy R., Cohen S. Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of mouse and cognition disorders. J. Neural Transm. [Suppl.]. 52:1997;287-300.
26. Speiser Z., Katzir O., Rehavi M., Zabarski T., Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavioral in the postnatal anoxia rat. Pharmacol. Biochem. Behav. 60:1998;387-393.
27. Tatton W.G., Chalmers-Redman R.M. Modulation of gene expression rather than monoamine oxidase oxidase inhibition: (-)-Deprenyl-related compounds in controlling neurodegeneration. Neurology. 47:1996;S171-S183.
28. Tatton W.G., Ju W.Y., Holland D.P., Tai C., Kwan M. Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J. Neurochem. 63:1994;1572-1575.
29. Youdim M.B.H. The advent of selective monoamine oxidase A inhibitor antidepressants devoid of the cheese reaction [91 Suppl.]. Acta Psychiatr. Scand. 387:1995;5-7.
30. Youdim, M.B.H., Finberg, J.P.M., Levy, R., Sterling, J., Lerner, D., Berger-Paskin, T., Yellin, H., 1995. R-Enantiomers of N-propargyl-aminoindan compounds. Their preparation and pharmaceutical composition containing them. United States Patent 5, 457, 133.
31. Youdim, M.B.H., Wadia, J.S., Tatton, W.G., 1999. Neuroprotective properties of the antiparkinson drug rasagiline and its optical S-isomer. Neurosci. Lett. (in press).
32. Wadia J.S., Chalmers-Redman R.M.E., Ju W.J.H., Varlilie G.W., Phillips J.L., Frase A.D., Tatton W.G. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J. Neurosci. 18:1998;932-947.